1-6 of 6
Richard Lush
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors

Jhanelle E. Gray, Eric Haura, Alberto Chiappori, Tawee Tanvetyanon, Charles C. Williams, Mary Pinder-Schenck, Julie A. Kish, Jenny Kreahling, Richard Lush, Anthony Neuger, Leticia Tetteh, Angela Akar, Xiuhua Zhao, Michael J. Schell, Gerold Bepler, Soner Altiok
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (6): 1644–1655.
https://doi.org/10.1158/1078-0432.CCR-13-2235
Published: 13 March 2014
View article titled, A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors
Open the PDF for A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors in another window
Journal Articles

Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial

Adil I. Daud, Jana Dawson, Ronald C. DeConti, Elona Bicaku, Douglas Marchion, Sem Bastien, Frederick A. Hausheer, III, Richard Lush, Anthony Neuger, Daniel M. Sullivan, Pamela N. Munster
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (7): 2479–2487.
https://doi.org/10.1158/1078-0432.CCR-08-1931
Published: 01 April 2009
View article titled, Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial
Open the PDF for Potentiation of a Topoisomerase I Inhibitor, Karenitecin, by the Histone Deacetylase Inhibitor Valproic Acid in Melanoma: Translational and Phase I/II Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer

Alberto A. Chiappori, Eric Haura, Francisco A. Rodriguez, David Boulware, Rachna Kapoor, Anthony M. Neuger, Richard Lush, Barbara Padilla, Michelle Burton, Charles Williams, George Simon, Scott Antonia, Daniel M. Sullivan, Gerold Bepler
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (5): 1464–1469.
https://doi.org/10.1158/1078-0432.CCR-07-1508
Published: 03 March 2008
View article titled, Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer
Open the PDF for Phase I/II Study of Atrasentan, an Endothelin A Receptor Antagonist, in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Advanced Non–Small Cell Lung Cancer in another window
Journal Articles

Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study

George R. Simon, Christopher R. Garrett, Stephen C. Olson, Michael Langevin, Irene A. Eiseman, John J. Mahany, Charles C. Williams, Richard Lush, Adil Daud, Pamela Munster, Alberto Chiappori, Mayer Fishman, Gerold Bepler, Peter F. Lenehan, Daniel M. Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (15): 4645–4651.
https://doi.org/10.1158/1078-0432.CCR-05-2379
Published: 09 August 2006
View article titled, Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study
Open the PDF for Increased Bioavailability of Intravenous Versus Oral CI-1033, a Pan erbB Tyrosine Kinase Inhibitor: Results of a Phase I Pharmacokinetic Study in another window
Journal Articles

A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors

Stacy L. Moulder, John J. Mahany, Richard Lush, Caio Rocha-Lima, Michael Langevin, Karen J. Ferrante, Lisa Michele Bartkowski, Shama M. Kajiji, Dennis A. Noe, Simone Paillet, Daniel M. Sullivan
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (21): 7127–7135.
https://doi.org/10.1158/1078-0432.CCR-04-0901
Published: 08 November 2004
View article titled, A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors
Open the PDF for A Phase I Open Label Study of the Farnesyltransferase Inhibitor CP-609,754 in Patients with Advanced Malignant Tumors in another window
Journal Articles

Sequential Intraperitoneal Topotecan and Oral Etoposide Chemotherapy in Recurrent Platinum-Resistant Ovarian Carcinoma: Results of a Phase II Trial

Anil K. Sood, Richard Lush, John P. Geisler, Mark S. Shahin, Linda Sanders, Dan Sullivan, Richard E. Buller, Joel I. Sorosky
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (18): 6080–6085.
https://doi.org/10.1158/1078-0432.CCR-04-0574
Published: 24 September 2004
View article titled, Sequential Intraperitoneal Topotecan and Oral Etoposide Chemotherapy in Recurrent Platinum-Resistant Ovarian Carcinoma: <subtitle>Results of a Phase II Trial</subtitle>
Open the PDF for Sequential Intraperitoneal Topotecan and Oral Etoposide Chemotherapy in Recurrent Platinum-Resistant Ovarian Carcinoma: <subtitle>Results of a Phase II Trial</subtitle> in another window